▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1201 by analyst upside · 2026-11-13
PRME
Prime Medicine, Inc.
Healthcare · Market Cap $706M · P/E 0x
ANALYST PRICE TARGET
+89.9%
implied upside to consensus target
Current Price $3.89
Consensus Target $7.39
Bull Target $11.0
Bear Target $4.25
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
8
Hold
2
Sell
0
52-Week Low $2.67
52-Week High $5.91
YTD Return +10.2%
FUNDAMENTALS
Market Cap $706M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.07
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $4M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $2.67
52-Week High $5.91
Current Price $3.89
Bear Target $4.25
Bull Target $11.0
● Now $3.89 ● Target $7.39
TRADING DATA
Avg Volume 4.3M
YTD Return +10.2%
Analyst Count 11
Consensus Buy
Upside to Target +89.9%
Last Updated 2026-11-13

ANALYST SUMMARY

Prime Medicine, Inc. (PRME) is currently trading at $3.89 with a Wall Street consensus price target of $7.39, implying potential upside of 89.9% over the next 12 months. 11 analysts currently cover PRME, with a consensus rating of Buy - 82% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.0, while the most cautious has a target of $4.25.

PRME operates in the Healthcare sector with a market capitalisation of $706M. The stock is up 10.2% year-to-date and is currently trading near the lower end of its 52-week range of $2.67 – $5.91.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PRME, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital - Reiterated
Buy → Buy 2026-09-25 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-08-25 33% win rate (6 calls)
BMO Capital ● Initiated
Outperform → Outperform 2026-08-19 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-08-10 31% win rate (48 calls)
HC Wainwright & Co. ↑ Upgrade
Neutral → Buy 2026-06-29 31% win rate (48 calls)
Oppenheimer ● Initiated
Outperform 2026-03-12 14% win rate (7 calls)
LifeSci Capital ● Initiated
Outperform 2025-12-23 Building track record
Citigroup - Reiterated
Neutral → Neutral 2025-11-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
19/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →